SCHEMBL1718082

SCHEMBL1718082

CCN(CC)c1cccc(-c2ccnc3[nH]ccc23)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 5/20 0.55
JAK2 O60674 2/20 0.54
PRKACA P17612 2/20 0.54
JAK3 P52333 2/20 0.54
PRKCQ Q04759 2/20 0.54
ROCK1 Q13464 2/20 0.54
ROCK2 O75116 1/20 0.54
PRKCA P17252 1/20 0.54
FLT3 P36888 1/20 0.54
GSK3B P49841 1/20 0.54
PRKCD Q05655 1/20 0.54
CCNK O75909 4/20 0.49
CDK12 Q9NYV4 4/20 0.49
NUDT1 P36639 5/20 0.47
IKBKB O14920 2/20 0.47
CHUK O15111 2/20 0.47
DAPK3 O43293 1/20 0.47
PRKD3 O94806 1/20 0.47
MAP4K4 O95819 1/20 0.47
PAK4 O96013 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1719354 0.81 PRKCI (0.53) PRKCIJAK2PRKACAJAK3PRKCQ
SCHEMBL1718159 0.81 NEK1 (0.51) PRKCIJAK2PRKACAJAK3PRKCQ
SCHEMBL10124899 0.80 PRKCI (0.58) PRKCIJAK2PRKACAJAK3PRKCQ
SCHEMBL27893877 0.80 PRKCI (0.52) PRKCIJAK2PRKACAJAK3PRKCQ
SCHEMBL12127819 0.78 PRKCI (0.63) PRKCIJAK2PRKACAJAK3PRKCQ
SCHEMBL12347990 0.78 PRKCI (0.56) PRKCIJAK2PRKACAJAK3PRKCQ
SCHEMBL1717883 0.77 CCNK (0.52) PRKCIJAK2PRKACAJAK3PRKCQ
SCHEMBL12346221 0.76 CIT (0.49) PRKCIJAK2PRKACAJAK3PRKCQ
SCHEMBL1717451 0.76 PRKCI (0.47) PRKCIJAK2PRKACAJAK3PRKCQ
SCHEMBL1718593 0.75 PRKCI (0.63) PRKCIJAK2PRKACAJAK3PRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921376-B2 Pyrrolopyridines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-12-30 US disclosed
US-8921376-B2 Pyrrolopyridines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-12-30 US disclosed
US-8921376-B2 Pyrrolopyridines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-12-30 US disclosed
EP-1881983-B1 PYRROLOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE VERTEX PHARMA (US) 2012-01-11 EP disclosed
EP-2354140-A1 Pyrrolopyridines useful as inhibitors of protein kinase Vertex Pharmaceuticals Incorporated (US) 2011-08-10 EP disclosed
EP-2354139-A1 Pyrrolopyridines useful as inhibitors of protein kinase Vertex Pharmaceuticals Incorporated (US) 2011-08-10 EP disclosed
CN-101228161-A Pyrrolopyridines useful as protein kinase inhibitors VERTEX PHARMA (US) 2008-07-23 CN disclosed
US-20070135466-A1 Pyrrolopyridines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED 2007-06-14 US disclosed
US-20070135466-A1 Pyrrolopyridines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED 2007-06-14 US disclosed
US-20070135466-A1 Pyrrolopyridines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135466-A1 Pyrrolopyridines useful as inhibitors of protein kinase JAK2, JAK1, JAK3 PRKCI 23/4885JAK2 1/4885PRKACA 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.